Trial Profile
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms BAX855 PUP study
- Sponsors Baxalta; Shire; Takeda
- 20 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 02 May 2023 The trial has been completed in Denmark, according to European Clinical Trials Database record.
- 22 Aug 2022 Planned End Date changed from 29 Jun 2023 to 31 Oct 2024.